3M Submits Aldara For Actinic Keratosis, Plans Carcinoma Filing Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
3M could gain two new indications for its topical immune response modifier Aldara in 2004, with a recent submission for actinic keratosis and a filing for basal cell carcinoma planned for this summer.
You may also be interested in...
3M Aldara submission
3M submits sNDA for use of its topical immune response modifier Aldara (imiquimod cream, 5%) for superficial basal cell carcinoma. The submission is based on two six-week, double-blind, placebo-controlled studies in 724 patients. The studies found dosing five times a week to be the optimal regimen, with a histological clearance rate of 82% vs. 3% for placebo. Aldara could also be cleared for another indication in 2004; 3M submitted an sNDA May 5 for actinic keratosis (1Pharmaceutical Approvals Monthly June 1, 2003, p. 15)...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product